1. Less Until None: A Plan for a World without T1D

2. 2 LESSUNTILNONE 2 JDRF’s Vision for the Future

3. 3 Mission: Less Until None Danger LESS Complexity LESS Invasive LESS Burden LESSUNTILNONE LESS UNTIL NONE

4. 4 TherapiesCure Delivery of Continuous Therapeutic Improvements Side-Effects Complications Patient Burden Glycemic Control Safety Normal Physiology Restored Better Safety, Fewer Side-Effects, Less Exposure to Complications

5. 5 $$$$$$$$$$ Discovery Research Clinical Development Regulatory Delivery to Patients ADVOCACYRESEARCHADVOCACYRESEARCHADVOCACYRESEARCH

6. 6 Discovery Research Clinical Development Regulatory Delivery to Patients ADVOCACYRESEARCHADVOCACYRESEARCHADVOCACYRESEARCH Investment $$$$$$$$$$

7. 7 Near TermMedium TermLong Term Complications Diabetic Eye Disease Insulin Pumps Infusion Artificial Pancreas Low Glucose Suspend Complications Predictive Diagnosis Artificial Pancreas Treat-to-Range Prevention Secondary Prevention Artificial Pancreas Treat-to-Target Artificial Pancreas Multihormone Encapsulation Implantable Islets Control Glucose Responsive Insulin Prevention Primary: Vaccine Complications Comprehensive Prevention Therapy Regeneration This timeline is based on clinical delivery goals of identified therapies and will be updated as progress is achieved

8. 8 Artificial Pancreas Automated technologies to help maintain better control of blood- glucose levels Integrated smart technology to automate routine elements of insulin management FDA released final guidance on pathway for commercialization of devices

9. 9 Glucose Responsive Insulin (GRI) Form of insulin that activated when blood-glucose levels start to rise Simplifies life for and improves overall blood-glucose controls JDRF competition underway to accelerate progress on GRI

10. 10 Encapsulation Easily implantable Beta cells or islets surrounded by a protective shield/capsule Able to sense glucose levels and produce insulin as needed Hidden from the immune system to sustain normal function Eliminating the need for immunosuppressive drug therapy

11. 11 Regeneration Ability to create new insulin producing cells destroyed by autoimmune attack Creating abundant supply of Beta cells through stem cells and regeneration Immune therapy for suspected “triggers” including viruses

12. 12 Secondary Prevention Preserve beta cell function in these newly diagnosed individuals Approaches include: Reducing inflammation Boosting beta cell survival Suppressing the autoimmune attack

13. 13 Primary Prevention Prevent the autoimmune attack on beta cells before it starts Approaches include: Viral vaccines Beta Cell Autoantigen Vaccines

14. 14 Funding Scale and Scope R&D Expertise

15. 15 Funding Scale and Scope R&D Expertise

16. 16 More = Less T1D Funding$$$ Funding $$$ Funding $$$ LESS UNTIL NONE Funding

17. 17